![Company](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CMN_Companies_to_Follow_2023_01_17_81d7a58868_1c503a0f51.png)
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Iovance Biotherapeutics
Main focus: Tumor infiltrating lymphocyte (TIL) therapies for the treatment of cancer
Company stage: Clinical
Diseases (gene editing): Cancer
Genome editing tool: TALEN
Funding stage: Public (NASDAQ:IOVA)
Location: San Carlos, CA, USA
Website: https://www.iovance.com/
Pipeline: https://www.iovance.com/clinical/pipeline/
Gene-editing partnerships: Cellectis
![](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iovance_697b84b5b1_eb0af13186.png)
Iovance Biotherapeutics is a clinical stage company focusing on the development of cellular therapies. The company develops tumour infiltrating lymphocyte (TIL)-based therapies to treat various types of solid tumours. The company's engagemen in the gene-editing space comes through its collaboration with Cellectis, from which it has licenced the TALEN technology to develop PD-1 inactivated TILs.